KKUR OTC
ChromoCure, Inc.
1W: +0.0%
1M: +0.0%
3M: -90.0%
YTD: +0.0%
1Y: +0.0%
3Y: -99.8%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾
Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000001-0.0001
Volume100,000
Avg Volume3,143,431
Beta-0.07
Dividend—
Analyst Ratings
No analyst coverage
Company Info
Employees4
SectorHealthcare
IndustryMedical - Specialties
IPO Date2005-04-27
Reno
US
About ChromoCure, Inc.
ChromoCure, Inc. specializes in designing and delivering exclusive systems for cancer identification. Their primary offering, the Chromosomal Scanner Series 200, is a detection system capable of identifying a distinct genomic characteristic that is universally present in all cancers yet entirely absent in healthy cells. Furthermore, the company dedicates its scientific and technological expertise to investigating non-toxic and non-invasive strategies for both cancer treatment and cure research. Established in 2001 and based in Reno, Nevada, the organization rebranded as ChromoCure, Inc. in June 2009, having previously been known as Cyberhand Technologies International, Inc.
Latest News
No recent news
Recent Insider Trades
No insider trades found